PCV58 CLINICAL AND ECONOMIC ISSUES IN THE PREVENTION OF VENOUS THROMBOEMBOLISM IN HOSPITALIZED ORTHOPEDIC PATIENTS: ENOXAPARIN VERSUS WARFARIN  by Balu, S et al.
278 Abstracts
plasma glucose (FPG) were obtained. The deﬁnition of metabolic
syndrome encompasses three or more of the following abnor-
malities: WHR >0.9 in men and >0.85 in women, BMI 
>23kg/m2, BP >140/>90mmHg, FPG >110mg/dL, HDL 
<40mg/dL in men and <50mg/dL in women, FTG >150mg/dL.
RESULTS: Data were available in 686 Korean American sub-
jects, 62% females. The prevalence of metabolic syndrome in our
sample was 25%. Frequency of elevated BP, elevated TG, low
HDL, and FPG were 32%, 21%, 29%, and 12%, respectively. 
Overall obesity, measured by BMI, was 35% and centrally
obesity, measured by WHR, was 35%. When compared between
men and women, the prevalence of metabolic syndrome in 
men was 32% and 20% seen among the women (95% CI, 
0.061, 0.198; p < 0.001); increased central adiposity was similar
in both men (35%) and women (35%); and FPG was signiﬁ-
cantly elevated in men (18%) than in women 9% (95% CI,
0.035, 0.142; p = 0.001). CONCLUSION: Multiple metabolic
disorders are present in the Korean Americans. Early detection
and treatment of hypertension, dyslipidemia, obesity, and
glucose intolerance can prevent the progression of diabetes 
mellitus and CVD.
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OBJECTIVES: 1) To examine the differences in models of meta-
bolic syndrome developed using exploratory factor analysis
(EFA) versus conﬁrmatory factor analysis (CFA) in the Insulin
Resistance Atherosclerosis Study (IRAS) population; and 2) To
measure validity and reliability of the variables used to measure
each factor. METHODS: The subjects were from a previously
studied cohort of 1087 nondiabetic participants in the IRAS, a
study of the relationships among insulin resistance and cardio-
vascular disease risk factors. Data from this study were used to
test two hypothesized models. In the ﬁrst model, previously
developed using EFA, two latent factors were proposed: a
“hypertension factor;” and a “metabolic factor,” consisting of
variables measuring obesity, hyperlipidemia, and obesity status”.
The second hypothesized model consisted of four-factors (hyper-
tension, hyperlipidemia, insulin resistance, and obesity). A CFA
was performed testing the hypothesized models using EQS Mul-
tivariate Software Version 5.7b with maximum likelihood esti-
mation. Construct validity and reliability of the variables used
to measure the factors were then assessed in the model with best
ﬁt. RESULTS: The 4-factor model exhibited better ﬁt than the
2-factor model using criteria established by Hu and Bentler 
(chi-square = 377.3, df = 5). The ﬁnal four-factor model exhib-
ited a good ﬁt (CFI = 0.963, SRMR = 0.036, RMSEA = 0.077).
There were signiﬁcant intercorrelations between all the hypoth-
esized factors. A residual variance correlation was required
between the insulin sensitivity index variable and the fasting
glucose variable. All factors except the lipid factor (measured
using HDL and triglycerides) exhibited good values for construct
reliability and variance extracted. CONCLUSION: The results
of this analyses show that metabolic syndrome is best explained
by a four-factor model in the IRAS population, rather than the
previously described two-factor model that was developed using
EFA. The hyperlipidemia factor is not well deﬁned, and suggests
that additional variables may be required to adequately measure
this factor.
CARDIOVASCULAR DISEASE—Thrombosis Including
DVT
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COST OF MAJOR BLEEDING FOLLOWING MAJOR
ORTHOPEDIC SURGERY
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OBJECTIVES: While effective in reducing the risk of venous
thromboembolism (VTE) following major orthopedic surgery
(MOS), antithrombotics can increase the risk of major bleeding.
We assessed impact of major bleeding following MOS on length
of stay (LOS) and inpatient charges. METHODS: Using a data-
base containing information on ~750,000 admissions annually
to 100+ US acute-care hospitals (MQProﬁle, Cardinal Informa-
tion Corp.), we identiﬁed all patients whom underwent MOS
between January 1, 1998 and December 13, 2000. Patients were
stratiﬁed according to whether or not they experienced major
postoperative bleeding prior to hospital discharge, deﬁned as: 
a) fatal bleeding; b) nonfatal bleeding at critical site; c) re-
operation due to bleeding; and d) overt bleeding with bleeding
index (BI) > 2, where BI = number of blood units transfused plus
pre-bleeding minus post-bleeding hemoglobin (g/dL) values. LOS
and inpatient charges were compared between patients with and
without major bleeding; ﬁndings were also examined for each of
the constituent measures of the composite endpoint. RESULTS:
A total of 23,518 patients were identiﬁed who underwent MOS;
2.6% experienced major bleeding (fatal bleeding, 0.1%; non-
fatal bleeding at a critical site, 0.2%; re-operation due to bleed-
ing, 0.7%; and overt bleeding associated with a BI > 2, 1.7%).
In multivariate analyses controlling for differences in baseline
characteristics between patients with and without major bleeds,
adjusted mean LOS was 1.8 days longer (95% CI: 1.5, 2.0)
among the former (6.1 days vs. 4.3 days for those without
bleeds); adjusted mean inpatient charges were $7593 higher
(95% CI: $6622, $8646) ($25,669 vs. $18,076). CONCLU-
SION: Major bleeding following MOS signiﬁcantly increases
LOS and hospital charges. Small absolute increases in the risk of
major bleeding may translate into additional costs of inpatient
care that counterbalance cost savings associated with VTE events
averted. Cost of major bleeding following MOS should factor
into choice of VTE prophylaxis.
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OBJECTIVES: Current American College of Chest Physicians’
guidelines recommend Venous Thromboembolism (VTE) pro-
phylaxis for orthopedic patients. This study examines prophy-
lactic therapy received by hospitalized orthopedic patients, rate
of secondary diagnosis of VTE, and compares overall hospital
costs by major cost-centers among enoxaparin and warfarin-
treated patients in order to rationalize drug use. METHODS: An
administrative database of 720,982 discharges containing ICD-
9-CM coding and other data from hospitals across the U.S. was
analyzed. Study patients were those whom underwent hip or
knee replacement procedures, and were prescribed warfarin or
enoxaparin. Length of stay (LOS), age, gender, number of diag-
noses (ND), and in-hospital deaths were compared between 
warfarin and enoxaparin cohorts using independent t-tests 
and chi-squared analysis. Least-squares regression was used to
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compare overall hospital costs between the two cohorts, con-
trolling for differences in variable distribution. RESULTS: From
9234 patients who met the inclusion criteria, 4972 patients
(53.8%) were prescribed warfarin and 5727 (62.0%) were
females. Overall rate of secondary diagnosis of VTE was 0.08%
(seven of 9241 patients; two enoxaparin and ﬁve warfarin
patients). Apart from LOS (p = 0.8089), NSD (p = 0.2421), and
gender (p = 0.4223), distribution of age (p < 0.0001) and in-
hospital deaths (p = 0.0045) were found to be signiﬁcantly dif-
ferent between the two cohorts. Overall mean hospital costs 
were found to be different (p < 0.0001) ($11,723.3 for warfarin
patients versus $11,963.9 for enoxaparin patients), after con-
trolling for signiﬁcant differences. Enoxaparin patients incurred
higher Medical/Surgical supplies ($616.7) and drugs/pharmacy
($312.1) expenses, while warfarin patients incurred more on
Operating-and-Recovery rooms ($766.4), Medical/Surgical
acute units ($487.3), and Laboratory ($39.6). CONCLUSIONS:
Overall rate of secondary diagnosis of VTE is very low for ortho-
pedic patients given prophylaxis; however, warfarin prophylaxis
showed a higher rate. Enoxaparin demonstrated a better clinical
outcome, but warfarin was signiﬁcantly less expensive. Further
research is needed to reconcile the clinical versus ﬁnancial
outcome ﬁndings from these analyses.
ENDOCRINE DISORDERS
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Fixed dosing increments in injectable devices may lead to poten-
tial inefﬁciencies such as overdosing in weight-based regimens.
Finer dosing increments can reduce product wastage and trans-
late into cost savings. OBJECTIVE: To compare overdosage and
wastage (therefore cost) due to Norditropin NordiFlex® 5mg 
to that of other somatropin (human growth hormone, rDNA
origin) delivery systems (Norditropin NordiPen® 5mg,
Genotropin® 5mg, Humatrope® 6mg, and Nutropin® 10mg)
in children. METHODS: Total recommended daily dose of
somatropin was calculated over a range of body weights and
weight-based (mg/kg) dosing regimens. Only body weights
resulting in a daily dose up to the maximum allowable dose for
each delivery system were considered. The amount of product
dispensed at each dose was determined based on dosing incre-
ments for each delivery system. Dosing increments for
Norditropin NordiFlex® were 0.025mg, compared to 0.05–0.2
mg for other delivery systems. The amount of somatropin admin-
istered by Norditropin NordiFlex® and associated annual costs
were compared with other somatropin delivery systems. Drug
costs were based on current wholesale acquisition costs (WAC).
RESULTS: At a daily dose of 0.030mg/kg, product wastage in
Norditropin NordiFlex® was 5.3%, 3.8%, 3.8%, and 1.8%
lower than Humatrope®, Nutropin®, Genotropin® and
Norditropin NordiPen®, respectively. The annual cost due to
Norditropin NordiFlex® was estimated at $14,580, and was
$811, $570, $390, and $265 lower than Humatrope®,
Nutropin®, Genotropin®, and Norditropin NordiPen®, respec-
tively. Greater savings (7.3%) were seen in lower body-weight
groups. At a higher daily dose of 0.043mg/kg, product wastage
(and corresponding annual cost) in Norditropin NordiFlex® was
6.1% ($1006), 4.2% ($684), 4.2% ($491), and 2.2% ($358)
lower than Humatrope®, Nutropin®, Genotropin®, and
Norditropin NordiPen® respectively. CONCLUSION: Com-
pared to other delivery systems, Norditropin NordiFlex®
reduces overdosage and wastage of growth hormone, conse-
quently resulting in meaningful cost savings.
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About 20,000 children in the US receive somatropin (human
growth hormone, rDNA origin) for the treatment of growth
hormone deﬁciency (GHD), with approximately 4000 new cases
annually. While the cost-effectiveness of somatropin for the treat-
ment of GHD has been assessed in the UK, to our knowledge 
no estimates for the US have been reported. OBJECTIVE: To
generate estimates of cost-effectiveness/utility of Norditropin® 
(r-DNA somatropin) in the treatment of GHD in children.
METHODS: A decision-analytic model of the epidemiology and
treatment of GHD in children was developed. Treatment of
GHD was assessed in two hypothetical cohorts compared to no
treatment–treatment with Norditropin® 0.030mg/kg/day from
ages ﬁve through 16 years, and treatment from ages three
through 18 years. Costs included those related to drug acquisi-
tion, endocrinologist consultations, and primary care ofﬁce
visits. Estimates of patient weight by age and sex were derived
from published literature, as was the proportion of patients
achieving normal height through Norditropin® treatment and
pre/post-treatment patient utilities. Cost-effectiveness/utility was
estimated over patients’ expected lifetimes, and was stated alter-
natively as discounted (3% per annum) US dollars per normal
height year (NHY) gained, and cost per quality adjusted life-year
(QALY) gained. Multivariate sensitivity analyses were conducted
to ensure robustness of the model. RESULTS: The cost-
effectiveness and cost-utility of treating children from ages ﬁve
through 16 years with Norditropin® was estimated at $8909 per
NHY gained and $36,955 per QALY gained, respectively. Treat-
ment of children from ages three through 18 years was estimated
to cost $9277 per NHY gained and $42,556 per QALY gained.
Findings were relatively insensitive to variation in most model
parameters. CONCLUSION: For both age cohorts, the cost-
effectiveness/utility of Norditropin® in the treatment of GHD
compares favorably to well-accepted threshold values. Thus,
Norditropin® represents excellent value for money for the treat-
ment of GHD in children.
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OBJECTIVE: To derive health status values (utilities) for the
Swedish population. METHODS: EQ-5D data were collected
through a mailing survey to a random sample (n = 2990) of the
Swedish population (response rate 65%: complete data on 1741
(49.4% males; mean age 48.4). The model was estimated using
the Jackknife method and multiple regression analysis. The full
sample was randomly divided into 10 parts of approximately the
